Fig. 1 · Structure

Documents & Downloads

Rolapitant

Cat. No. A13680 CAS 552292-08-7

NK1 receptor antagonist

Rolapitant, also known as SCH-619734, is a selective, bioavailable, CNS penetrant neurokinin NK1 receptor antagonist that shows behavioral effects in animals models of emesis.

In Stock

Publications for Rolapitant

1 publication citing this product

  1. Bubak AN, .et al. , J Infect Dis, 2018, Sep 8;218(8):1324-1335 PMID: 29788447

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
human NK1 Ki 0.66 nM
gerbil NK1 Ki 0.13 nM
guinea pig NK1 Ki 0.72 nM
monkey NK1 Ki 2.5 nM
rabbit NK1 Ki 31.7 nM
rat NK1 Ki 78.6 nM
mouse NK1 Ki 60.4 nM

7 targets · Scroll to view more

Rolapitant Research Summary

This section summarizes 2 in vitro studies of Rolapitant from 1 published reference. In vitro models include purified OTUD3 OTU domain and K48-linked di-ubiquitin.

Rolapitant In Vitro Studies

Rolapitant reduced 72-hour CCK-8 viability in four human lung cancer cell lines, with reported IC50 values of 10.70–13.90 μM. BEAS-2B normal lung epithelial cells had an IC50 of 19.69 μM, indicating a limited separation in this assay. [1]

A separate purified-protein assay found that 10 μM rolapitant inhibited OTUD3-mediated K48-linked di-ubiquitin cleavage. This qualitative observation supplies neither an OTUD3 IC50 nor a selectivity profile. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Rolapitant concentration response in lung cancer and normal epithelial cells

Cell-based study · A549, H1299, H460 and H1975 human lung cancer cells; BEAS-2B normal lung epithelial comparator [1]

After 72 hours, reported CCK-8 IC50 values ranged from 10.70 to 13.90 μM in the four cancer cell lines, compared with 19.69 μM in BEAS-2B. The normal-cell comparator also had a finite IC50; these data do not establish absence of normal-cell toxicity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
72-hour CCK-8 cell viability in A549IC50 10.70 μM[1]
72-hour CCK-8 cell viability in H1299IC50 13.90 μM[1]
72-hour CCK-8 cell viability in H460IC50 11.30 μM[1]
72-hour CCK-8 cell viability in H1975IC50 12.05 μM[1]
72-hour CCK-8 cell viability in BEAS-2BIC50 19.69 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–40 μM rolapitant concentration range, Figure 2A caption
Exposure duration
72 h
Method
Cell treatment followed by CCK-8 viability assessment
Vehicle
DMSO comparator in shared Cell viability assays method; final DMSO percentage not stated.
Reported limits
IC50 confidence intervals and final DMSO percentage are not reported in the adopted locations. Values use the Results text; Figure 2A labels round H1975 and BEAS-2B to 12.1 and 19.7 μM.
Methods and source locations

Compound reported in the paper: Rolapitant; Compound label in the paper: S5476 (Selleck)

Literature findings for the reported rolapitant reagent; no Adooq lot validation or salt conversion.

Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources

72-hour CCK-8 cell viability in A549: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources

72-hour CCK-8 cell viability in H1299: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources

72-hour CCK-8 cell viability in H460: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources

72-hour CCK-8 cell viability in H1975: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources

72-hour CCK-8 cell viability in BEAS-2B: CCK-8 absorbance at 450 nm; nonlinear regression in GraphPad Prism. Figure 2 reports mean ± SD, n = 3 independent experiments; no IC50 uncertainty supplied. — Figure 2A and caption; Results, Rolapitant inhibits lung cancer cell growth by targeting OTUD3, first paragraph; Methods, Cell viability assays and Cell lines and drug sources

Purified OTUD3-mediated di-ubiquitin cleavage

Biochemical assay · Purified OTUD3 OTU domain (amino acids 52–209) and K48-linked di-ubiquitin [1]

At 10 μM, rolapitant inhibited OTUD3-mediated K48-linked di-ubiquitin cleavage relative to the enzyme and DMSO controls. The blot provides a qualitative activity result; it does not determine an IC50 or establish selectivity over other deubiquitinases.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
K48-linked di-ubiquitin cleavage by purified OTUD3 OTU domainQualitative immunoblot result Inhibited cleavage at 10 μM rolapitant[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM rolapitant
Exposure duration
3 h
Method
Purified-protein deubiquitination reaction at 37°C followed by western blot
Vehicle
DMSO comparator; final percentage not stated.
Reported limits
No concentration-response IC50, quantitative inhibition percentage or final DMSO percentage is supplied for Figure 3E.
Methods and source locations

Compound reported in the paper: Rolapitant; Compound label in the paper: S5476 (Selleck)

Literature findings for the reported rolapitant reagent; no Adooq lot validation or salt conversion.

Figure 3E and caption; Results, Rolapitant inhibits the deubiquitinating activity of OTUD3, paragraph beginning Next, we performed in vitro deubiquitination assays; Methods, In vitro deubiquitination assays and Cell lines and drug sources

K48-linked di-ubiquitin cleavage by purified OTUD3 OTU domain: Western blot after 3 h at 37°C. Figure 3 panels are described as representative of three or more independent experiments. — Figure 3E and caption; Results, Rolapitant inhibits the deubiquitinating activity of OTUD3, paragraph beginning Next, we performed in vitro deubiquitination assays; Methods, In vitro deubiquitination assays and Cell lines and drug sources

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 552292-08-7
Applications NK1 receptor antagonist
Formula C25H26F6N2O2
Molecular Weight 500.5
Synonyms SCH619734
SMILES
C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)C4=CC=CC=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Rolapitant Research References

  1. [1] Tongde Du, Quan Gu, Yonghui Zhang, et al. Rolapitant treats lung cancer by targeting deubiquitinase OTUD3 Cell Communication and Signaling (2024). PMID: 38539203 DOI: 10.1186/s12964-024-01519-8 Source material

Publications

1 publication citing this product

  1. Bubak AN, .et al. , J Infect Dis, 2018, Sep 8;218(8):1324-1335 PMID: 29788447

Added to your cart

View Cart Checkout
Loading...